Acorda Therapeutics, Inc.
DURABLE TREATMENT WITH 4-AMINOPYRIDINE IN PATIENTS WITH DEMYELINATION
Last updated:
Abstract:
Disclosed herein are methods and compositions related to the durable use of aminopyridines, such as 4-aminopyridine, to improve impairments of patients with a demyelinating condition, such as MS.
Status:
Application
Type:
Utility
Filling date:
6 Dec 2019
Issue date:
16 Apr 2020